LETTER TO EDITOR

Novel ADA2 Compound Heterozygous Mutations Resulting in Deficiency of Adenosine Deaminase 2 in a Pair of Siblings

Li Guo 1, Jun Wang 2, Xinghui Yang 3, Rongjun Zheng 1, Natalie Deuitch 4, Panfeng Tao 2, Qing Zhou 2

Received: 31 July 2020 / Accepted: 21 January 2021 / Published online: 30 January 2021
© The Author(s) 2021

To the Editor,

The deficiency of adenosine deaminase 2 (DADA2) is an autoimmune inflammatory disease caused by biallelic loss-of-function mutations in the ADA2 gene. Approximately 200 cases have been reported worldwide [1] since it was first described in 2014 [2, 3]. While the exact prevalence of DADA2 is unknown, it could be as high as 4:100,000 [4]. DADA2 is a clinically heterogeneous disease, and phenotypes include a spectrum of vasculopathy/vasculitis, immune dysregulation, and/or hematologic abnormalities [4–6]. The most common pathogenic variants of ADA2 are p.G47R and p.R169Q [6, 7]. However, the pathogenesis of DADA2 is still not clear. Tumor necrosis factor (TNF) inhibitors have been proven to be highly effective in treating vasculitic forms of DADA2 [4, 8]; however, they seem to be less effective when it comes to cases manifesting as immunodeficiency or bone marrow failure [4]. In some cases, hematopoietic stem cell transplantation (HSCT) can be beneficial for individuals with bone marrow failure, severe immunodeficiency, or for patients who do not respond to TNF inhibition [4, 6].

Case Report

Here we report the case of a 9yo Chinese boy who presented with a history of livedo reticularis (Fig. 1a, b) and recurrent fevers that began around 1 month of age. He had an ischemic stroke at 2yo and another at 8yo followed by a hemorrhagic stroke that same year. At the time of each of his strokes, he was treated with high-dose intravenous methylprednisolone, oral prednisone, and high-dose intravenous immunoglobulin (IVIG). However, he was still left gait instability, dysarthria, poor fine motor, and minor cognitive impairment. Laboratory work up showed elevated white blood cell counts and mild anemia as well as slightly elevated C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Serum cytokines levels (including interleukin (IL)-2, IL-4, IL-6, IL-10, TNF-α, and interferon (IFN)-γ) were assessed using cytometric bead array techniques and IL-6 and IL-10 were found to be elevated (Table 1). T/B/NK cell counts by flow cytometry indicated that while the proportion of CD3⁻CD16⁺CD56⁺ NK cells was relatively low, the proportion of CD3⁺CD4⁺ T cells was relatively high and the ratio of CD3⁺CD4⁺ T cells and CD3⁺CD8⁺ T cells was also elevated. Serum immunoglobulin (Ig) and complement (C) testing revealed that IgM was notably low, while C4 was elevated (Table 1).

Magnetic resonance imaging (MRI) showed abnormal signals in the right thalamus, which were determined to be inflammatory lesions (Fig. 1d). In addition, the MRI showed abnormal signals of medulla oblongata and pontine, and small softening foci in pons and right thalamus (Fig. 1e). Magnetic resonance venography (MRV) demonstrated bilateral transverse sinus narrowing, and local signal interruption, which suggested bilateral transverse sinus thrombosis (Fig. 1f). Computerized tomography (CT) detected a hemorrhagic lesion in left temporal lamella and calcification in the left globus pallidus (Fig. 1g). All imaging studies detected significant sinusitis (Fig. 1h).

Whole exome sequencing (WES) revealed two missense mutations in ADA2: c.50C > G (p.R169G) which was
IgG, IgA, and C4 (Table 1). MRI imaging has remained normal.

While p.R169Q is a well-known pathogenic variant in ADA2, p.R169G has not previously been reported in the literature. Structure modeling by PyMOL showed that it significantly altered the putative receptor-binding domain in a similar manner to R169Q (Fig. 1m). It was similar predicted to be inherited maternally and c.142G>A (p. G48R) which was inherited paternally (Fig. 1j, k, l). These variants were also detected in his 3-year-old sister who appeared to be unaffected at the time of testing (Fig. 1i); however, 1 year later, she developed livedo reticularis on her face and limbs (Fig. 1e). Laboratory work up also showed mild anemia, mildly elevated CRP and ESR, and as well as elevated IL-6, IL-10, IFN-γ, IL-4, and C3 (Table 1).  

Table 1  Laboratory features of patients with DADA2

| Laboratory features | Normal range | Brother Before Anti-TNF treatment | Sister After Anti-TNF treatment |
|---------------------|--------------|----------------------------------|--------------------------------|
| CBC                 |              |                                  |                                |
| WBC (× 10^9/L)      | 4.0–12.0     | 15.84†                          | 11.90                          |
| Hb (g/L)            | 110–155      | 91↓                             | 105↓                           |
| PLT (× 10^9/L)      | 100–400      | 535↑                            | 453↑                           |
| CRP (mg/L)          | 0–8          | 23↑                             | 12↑                            |
| ESR (mm/h)          | 0–20         | 47↑                             | 13                             | 40↑                           | 18↑                           | 8↑                            | 49↑                           |
| Cytokines           |              |                                  |                                |
| IL-2 (pg/mL)        | 1.1–9.8      | 2.1                             | 1.3                            | 2.1                           | 1↑                            | 1.1                           | 1.0                           | 3.5                           |
| IL-4 (pg/mL)        | 0.1–3.0      | 1.5                             | 1.0                            | 1.9                           | 1.8                           | 4.0                           | 4.0                           | 1.9                           |
| IL-6 (pg/mL)        | 1.7–16.6     | 35.2↑                           | 22.0↑                           | 1389↑                         | 32.8↑                         | 4.6                           | 26.3↑                         |                                |
| IL-10 (pg/mL)       | 2.6–4.9      | 7.0↑                            | 3.7                            | 6.4↑                           | 8.0↑                           | 6.1                           | 5.9↑                           |                                |
| TNF-α (pg/mL)       | 0.1–5.2      | 2.0                             | 1.0                            | 1.0                           | 2.1                           | 83.8                          | 1.3                           |                                |
| IFN-γ (pg/mL)       | 1.6–17.3     | 14.7                            | 17.5↑                           | 16.9                          | 80.9↑                          | 16.4                          | 23.6↑                          |                                |
| IgG (g/L)           |              |                                  |                                |
| 5.44                | (3.22–7.18)  | 12.16                           | (3.82–10.58)                   | 15.9                          | (6.36–13.24)                   | 9.2                           | (6.36–13.24)                   | 9.50                          | (6.36–13.24)                   | 18.2↑                         | (5.00–10.60)                   |
| IgA (g/L)           | 0.18         | 0.52                            | 1.97                           | (0.13–0.35)                    | (0.14–1.14)                    | 1.5                           | (0.63–1.79)                    | 0.96                          | (0.63–1.79)                    | 2.36                           | (0.34–1.38)                    |
| IgM (g/L)           | 0.06↓        | 0.29↓                           | 0.27↓                           | (0.23–0.91)                    | (0.40–1.28)                    | 0.15↓                         | (0.29–1.21)                    | 0.30                          | (0.29–1.21)                    | 0.6                            | (0.44–1.44)                    |
| IgE (IU/L)          | 1–100        | 13.5                            | 99.9                           | 56                            | 18.9                          | 42.1                          | 54.4                           |                                |
| C3 (g/L)            | 0.9–1.8      | 1.43                            | 1.35                           | 1.41                          | 1.40                          | 1.10                          | 1.66                           |                                |
| C4 (g/L)            | 0.1–0.4      | 0.47↑                           | 0.51↑                           | 0.57↑                         | 0.47                          | 0.56↑                         |                                |                                |
| T/B/NK cells*       |              |                                  |                                |
| CD19* B cell (%)    |              | 27.15                           | (15.0–20.0)                     | 13.50                         | (15.0–20.0)                    | 18.00                         | (15.0–20.0)                    | 24.10                         | (15.0–20.0)                    | (19.0–29.0)                    |
| CD3+ T cell (%)     |              | 68.72                           | (53.0–74.0)                     | 67.5                           | (65.0–72.0)                    | 76.8                          | (65.0–72.0)                    | 65.00                         | (65.0–72.0)                    | 63.00                          | (62.0–70.0)                    |
| CD3+CD4+ T cell (%) |              | 46.15                           | (36.0–38.0)                     | 37.65↑                         | (27.0–34.0)                    | 42.00↑                         | (27.0–34.0)                    | 31.70                         | (27.0–34.0)                    | 39.90                          | (27.0–34.0)                    |
| CD3*CD8* T cell (%) |              | 18.00                           | (13.5–19.5)                     | 24.80                          | (23.0–30.0)                    | 29.10                          | (23.0–30.0)                    | 24.10                          | (23.0–30.0)                    | 19.40                          | (23.0–30.0)                    |
| CD4*/CD8*           |              | 2.56↑                           | (1.9–2.5)                       | 1.52↑                          | (1.0–1.4)                      | 1.44↑                          | (1.0–1.4)                      | 1.32                          | (1.0–1.4)                      | 2.06                           | (1.2–2.0)                      |
| CD3*CD16*CD56* NK cell (%) | 3.15↓ | (11.0–24.0)                 | 10.2↓                           | 7.20↓                          | 8.10                           |                                |                                |                                |                                |                                |                                |

*Because T/B/NK cell counts and serum IgG, IgA and IgM levels have different reference ranges at different ages, the corresponding reference ranges are indicated in parentheses following the data.
Deleterious/damaging by five in silico models including SIFT, PolyPhen-2, LRT, FATHMM, and PROVEAN. The p.G48R variant had been already reported in a Chinese literature by Wang et al. (http://rs.yiigle.com/CN141217201907/1156843.htm) and had been predicted to be pathogenic by several in silico models including SIFT, PolyPhen-2, LRT and PROVEAN.

Plasma ADA2 enzyme activity was found to be significantly decreased in the proband and his sister when compared to healthy age-matched controls (Fig. 1n) [7, 9]. To further determine the pathogenicity of R169G variant and R169Q variant on his own, we overexpressed wild type and mutant plasmid in HEK293T cells, and measured ADA2 enzyme activity in the medium and cell lysate 48 h after transfection. Both variants were found to decrease ADA2 activity in both the cell culture supernatant (Fig. 1o) and whole cell lysates (Fig. 1p). Additionally, the R169G and R169Q variants were found to affect the secretion of ADA2 into the cell supernatant (Fig. 1q).

We also studied the transcriptome profile of the siblings’ peripheral blood mononuclear cells (PBMCs) at baseline and upon lipopolysaccharide (LPS) stimulation (1 μg/ml) by RNA-seq. The proband’s PBMCs expressed increased levels of cytokines, including IL-6, TNF, IL-1β, and IL-10 both at a basal level and upon LPS stimulation when compared to an age-matched control (Fig. 1r), while his sister’s PBMCs only expressed moderately elevated IL-6 and IL-10 levels upon LPS stimulation compared to the healthy control (Fig. 1r).

Upon receiving the diagnosis, the proband began anti-TNF therapy (etanercept) [8]. He did not have another stroke after treatment. His fever quickly subsided on the second day of treatment. He was no longer anemic, and his CRP and ESR, and IL-6 had normalized at 3 months of treatment. But he was detected to have a new small lesion (Fig. 1i) on the brain upon MRI; however, the significance of this finding is unclear. After a year of treatment, his IgM also returned to normal level. His sister is still being followed; however, the family declined initiation of anti-TNF therapy for her.

**Discussion**

Here we report a case of two siblings with novel variants in ADA2. The elder brother had typical clinical manifestations of DADA2, presenting with livedo reticularis, recurrent fevers, two ischemic strokes, and one hemorrhagic stroke with symptoms first reported around 1 month old. The younger sister was asymptomatic until she appeared livedo reticularis at 4Y3M old. This may be attributable to a combination of known clinical heterogeneity, even within families, and age-related penetrance [10].

One variant (p.R169G, c.505C > G) we reported in these siblings is novel. Additionally, the p.R169G and p.R169Q affected the secretion of ADA2 in which may result in inflammation and tissue damage. However, the exact pathogenicity of these two variants remains unknown. Considering p.R169Q is one of most common pathogenic mutations in DADA2, this might help for further study of the pathogenicity of this mutation and the precise treatment for patients with this mutation. Although another variant (p. G48R, c.142G > A) is a novel mutation in gnomAD, it had been already reported as a pathogenic mutation. What’s more this mutation was also collected in infevers (https://infevers.umai-montpellier.fr/web/detail_mutation.php) in the 3rd International Conference on Deficiency of ADA2.

Proinflammatory IL-6 and anti-inflammatory IL-10 cytokines were highly expressed in both siblings. This supports the hypothesis that M1 and M2 imbalance drives inflammation in DADA2 [2]. It should be noted that IL-10 is a pleiotropic cytokine. It can play an important role in immunosuppression through inhibition of macrophage activation, but excessive secretion of IL-10 in response to tissue damage can also increase inflammation. Because of this it is unclear if IL-10’s role in DADA2 is protective or destructive. There is difference between the cytokine levels and cytokine expression profile in PBMCs detected by RNA-seq. This might result from that the sister had no symptoms at the time when RNA-seq was performed. Although the serum TNF-α level was normal, the proband’s PBMCs expressed increased TNF and he was successfully treated by TNF inhibition. However, his sister had no increased TNF both on PBMCs and in serum. This confirms that TNF plays an important role in the pathogenesis of DADA2 and the transcriptome profile by RNA-seq is a useful and sensitive technique to detect inflammatory cytokines. This reminds us that it is better to determine the cytokine levels by multiple techniques.

The diagnosis of DADA2 in seemingly unaffected individuals through molecular testing can often be challenging for families and clinicians to manage. Treatment with TNF inhibitors has been proven to be remarkably effective in DADA2 patients, particularly when it comes to the prevention of strokes [8]. Many experts feel that treatment should be initiated in all molecularly detected patients to prevent symptoms from developing, unless therapy is contraindicated as may be the case of patients presenting with immunodeficiency or bone marrow failure as a primary feature [4]. This case highlights the strong need for swift TNF inhibition as the proband had maintained fevers and elevated CRP on oral prednisone, and even had a stroke when the prednisone was tapered. However, his symptoms normalized and he has not had any significant strokes in the year since beginning treatment with TNF inhibition. The family opted out of treatment for the younger sister, given her relatively mild symptoms. While initiation of TNF inhibitors could prevent her from developing more serious symptoms, such as strokes, initiating therapy can burdensome for families, especially when it is unclear if an individual will ever develop more serious symptoms. Future guidance should be developed for treatment of pre-symptomatic, or asymptomatic, patients.
compound heterozygous/homozygous known disease causing gene

15X depth (SNP/INDEL) coding (MS/SS/stop/FS/NFS) rare variants (frequency< 1%) compound heterozygous/homozygous ADA2

IB: ADA2
IB: GAPDH
Supernatant
Cell lysates

Relative ADA2 activity

Control- LPS
Control- basal
proband- LPS
sister- LPS
proband- basal
sister- basal

IB: ADA2
IB: GAPDH
Clinical features of patients with DADA2 and identification of mutations in ADA2. 

- a-c Livedo reticularis on the trunk and limbs of the proband. 
- d Livedo reticularis on a leg of the sister. 
- e Axial T2WI showed a high signal nodule in the right thalamus with clear edges, which was a fresh infarction area (red arrow). 
- f ADC graph indicated a low signal patch area in the right part of the brainstem, which was an old infarction (red arrow). 
- g 2d-MRV demonstrated bilateral transverse sinus narrowing, and local signal interruption, which suggested bilateral transverse sinus thrombosis (red arrow). 
- h Calcification in the left globus pallidus (red arrow) and hemorrhagic stroke in the left temporal lobe (white arrow) were seen on CT image. 
- i Axial T2WI showed Maxillary sinusitis (red arrow). 
- j T2 dark-fluid indicated a new small lesion in the right lenticula (red arrow). 
- k Pedigree of the family with compound heterozygous mutations in ADA2. 

Conclusions

Here we reported a pair of siblings with DADA2 caused by novel compound heterozygous variants in ADA2. On a clinical level, this case highlights the intrafamilial clinical heterogeneity of DADA2 and demonstrates some of the complexities of detecting the conditions in seemingly unaffected individuals. Early detection of DADA2 is critical and on a molecular level, this case contributes one novel variant (p.R169G) which may be detected in additional patients in the future. On a physiologic level, cytokine profiling revealed highly expressed levels of IL-6, IL-10, IL-1β, TNF, and IFN-γ which may play a role in DADA2 pathogenesis.

Acknowledgements

We thank the patients and their family for the participation.

Author Contributions

All authors contributed to the study conception and design. LG provided clinical data and drafted the manuscript. JW and PFT performed experiments. JW analyzed the data and edited the manuscript. XHY and RJZ collected clinical data from the patients. ND provided valuable advice and edited the manuscript. QZ reviewed and edited the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the grants 31771548 and 81971528 from The National Natural Science Foundation of China, LR19H100001, from Zhejiang Provincial Natural Science Foundation of China.

Data Availability

All data generated or analyzed during this study are included in this published article.

Declarations

Ethics Approval, Consent to Participate, and Consent for Publication

This study was approved by the ethics committee of the Children’s Hospital, Zhejiang University School of Medicine, and the written consent of the family.

Conflict of Interest

The authors declare that they have no conflict of interest.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Clarke K, Campbell C, Omoyinmi E, Hong Y, Al Obaidi M, Sebire N, et al. Testicular ischemia in deficiency of adenosine deaminase 2 (DADA2). Pediatr Rheumatol. 2019;17(1):39. https://doi.org/10.1186/s12969-019-0334-5.
2. Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911–20. https://doi.org/10.1056/NEJMoa1307361.
3. Navon Elkan P, Pierce SB, Segel R, Walsh T, Barash J, Padhe S, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921–31. https://doi.org/10.1056/NEJMoa1307362.
4. Aksentijevich I, Sampaio Moura N, Barron K. Adenosine Deaminase 2 Deficiency. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle. Copyright © 1993–2020, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved; 1993.
5. Lee PY. Vasculopathy, immunodeficiency, and bone marrow failure: the intriguing syndrome caused by deficiency of adenosine deaminase 2. Front Pediatr. 2018;6(282). https://doi.org/10.3389/fped.2018.00282.
6. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): updates on the phenotype, genetics, pathogenesis, and treatment. J Clin Immunol. 2018;38(5):569–78. https://doi.org/10.1007/s10875-018-0525-8.
7. Lee PY, Kellner ES, Huang Y, Furutani E, Huang Z, Bainter W, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2). J Allergy Clin Immunol. 2020;145(6):1664–72.e10. https://doi.org/10.1016/j.jaci.2019.12.908.
8. Ombrello AK, Qin J, Hoffmann PM, Kumar P, Stone D, Jones A, et al. Treatment strategies for deficiency of adenosine deaminase 2.
9. Lee PY, Huang Y, Zhou Q, Schnappauf O, Hershfield MS, Li Y, et al. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. J Allergy Clin Immunol. 2018;142(4):1363–5.e8. https://doi.org/10.1016/j.jaci.2018.05.038.

10. Van Montfrans JM, Hartman EAR, Braun KPJ, Hennekam EAM, Hak EA, Nederkoorn PJ, et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations. Rheumatology. 2016;55(5):902–10. https://doi.org/10.1093/rheumatology/kev439.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.